LV305 + G305
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Synovial Sarcoma
Conditions
Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Trial Timeline
Sep 18, 2018 → Nov 20, 2018
NCT ID
NCT03520959About LV305 + G305
LV305 + G305 is a phase 3 stage product being developed by Merck for Synovial Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03520959. Target conditions include Synovial Sarcoma, Cancer, Soft Tissue Sarcoma.
What happened to similar drugs?
1 of 3 similar drugs in Synovial Sarcoma were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03520959 | Phase 3 | Terminated |
Competing Products
8 competing products in Synovial Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib | Daiichi Sankyo | Phase 2 | 39 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 44 |
| Pexidartinib | Daiichi Sankyo | Approved | 43 |
| Ramucirumab + Gemcitabine + Docetaxel | Eli Lilly | Phase 1/2 | 24 |
| TBI-1301 + Cyclophosphamide | Takara Bio | Phase 1/2 | 32 |
| TBI-1301 + Cyclophosphamide + Fludarabine | Takara Bio | Phase 3 | 47 |
| FHD-609 | Foghorn Therapeutics | Phase 1 | 11 |
| CFT8634 | C4 Therapeutics | Phase 1 | 11 |